# Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer

> **NCT06408038** · NA · COMPLETED · sponsor: **Institut Claudius Regaud** · enrollment: 60 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **OTHER:** For each patient included, the samples described below will be collected:

## Key facts

- **NCT ID:** NCT06408038
- **Lead sponsor:** Institut Claudius Regaud
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-25
- **Primary completion:** 2025-10-08
- **Final completion:** 2025-10-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-11-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06408038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06408038, "Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06408038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*